By irradiating targets in the world-class OPAL research reactor, a diverse set of radioisotopes, primarily for nuclear medicine, are available for a variety of applications and for research.
| Radioisotope | Half life | Emission type | Application |
|---|---|---|---|
| Chromium-51 | 27.7 days | γ | Tracing |
| Iodine-123* | 13.2 hours | (EC), γ | SPECT imaging |
| Iodine-131 | 8.02 days | β-, γ | Therapy |
| Lutetium-177 | 6.65 days | β-, γ | SPECT imaging/therapy |
| Technetium-99m | 6.01 hours | γ | SPECT imaging |
*Available for domestic use.
To complement this suite of OPAL-produced radioisotopes, we are working to extend this range by accessing:
- ANSTO commercial capabilities
- National partner cyclotrons
- Imports from international commercial radioisotope vendors
- Imports from collaborative international research reactors and accelerators
The availability of these radioisotopes will differ significantly depending on reactor scheduling and demand for non-routine custom irradiated products.
Fundamental to this capability, ANSTO provides well-equipped, licensed facilities and highly trained staff to handle SPECT-, PET- and therapeutically relevant radionuclides.
Please confirm the availability of your selected radioisotope with your ANSTO contact before submitting your proposal.
Dr Leena Burgess
